Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Jalra Trio for Management of Type 2 Diabetes in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Pioz-V for Uncontrolled Diabetic Patients with Fatty Liver","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Biogenomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"USV, Biogenomics Launch Biosimilar Insulin Aspart INSUQUICK","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Biosimilar","date":"November 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supplier can only Seek Advance Ruling under GST, Rules MAAR","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by USV Private Limited

    Menu

    USV Private Limited

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INTERMEDIATES

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              USV Private Limited

              Contact Supplier
              • Deals
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV, Biogenomics Launch Biosimilar Insulin Aspart INSUQUICK

              Details:

              Under the partnership, USV and Biogenomics launched Insuquick, India's first biosimilar insulin aspart, a rapid-acting analogue of insulin, for the treatment of diabetes.

              Lead Product(s): Insulin aspart

              Therapeutic Area: Endocrinology Product Name: Insuquick

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Biogenomics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership November 09, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients

              Details:

              Liralin (linagliptin) is a DPP-4 (Dipeptidyl peptidase IV) inhibitor, oral small molecule drug which is approved for the treatment of type-2-diabetes mellitus.

              Lead Product(s): Linagliptin

              Therapeutic Area: Endocrinology Product Name: Liralin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 04, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients

              Details:

              Roseday CV (rosuvastatin + clopidogrel) is a fixed dose combination which is approved for the treatment of cardiac diseases like heart attack, angina & stroke.

              Lead Product(s): Rosuvastatin,Clopidogrel

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Roseday CV

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Jalra Trio for Management of Type 2 Diabetes in India

              Details:

              Jalra-Trio (vildagliptin + dapagliflozin + metformin) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.

              Lead Product(s): Vildagliptin,Dapagliflozin,Metformin

              Therapeutic Area: Endocrinology Product Name: Jalra Trio

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 11, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Pioz-V for Uncontrolled Diabetic Patients with Fatty Liver

              Details:

              Pioz V (vildagliptin + pioglitazone) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.

              Lead Product(s): Vildagliptin,Pioglitazone

              Therapeutic Area: Endocrinology Product Name: Pioz V

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 25, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited

              Contact Supplier
              • Deals
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Supplier can only Seek Advance Ruling under GST, Rules MAAR

              Details:

              Under the agreement, USV acquires the trademark for antidiabetes drug Jalra (vildagliptin) and Jalra M (vildagliptin and metformin), used to treat type 2 diabetes mellitus, from Novartis.

              Lead Product(s): Vildagliptin

              Therapeutic Area: Endocrinology Product Name: Jalra

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Novartis Pharmaceuticals Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 22, 2021

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY